Results 21 to 30 of about 18,762 (211)

Real-World Analysis of Therapeutic Patterns in Patients Affected by Rheumatoid Arthritis in Italy: A Focus on Baricitinib

Rheumatology and Therapy, 2020
Introduction The objective of this study was to evaluate treatment patterns in patients with rheumatoid arthritis (RA), with a focus on the utilization of baricitinib, an oral highly selective Janus kinase 1 and 2 inhibitor, in an Italian real-world ...
Valentina Perrone, Serena Losi, Veronica Rogai, Silvia Antonelli, Walid Fakhouri, Massimo Giovannitti, Elisa Giacomini, Diego Sangiorgi, Luca Degli Esposti   +8 more
doaj   +1 more source

Rheumatoid arthritis [PDF]

, 2016
Rheumatoid arthritis is a chronic inflammatory joint disease, which can cause cartilage and bone damage as well as disability. Early diagnosis is key to optimal therapeutic success, particularly in patients with well-characterised risk factors for poor ...
Aletaha, Daniel, McInnes, Iain B., Smolen, Josef S.   +2 more
core   +1 more source

Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19

Frontiers in Medicine, 2021
Background: Baricitinib is a Janus kinase (JAK) inhibitor with a broader anti-inflammatory activity than tocilizumab and an antiviral potential although no head-to-head trials are available.
Mar Masiá, Sergio Padilla, José Alberto García, Javier García-Abellán, Andrés Navarro, Lucía Guillén, Guillermo Telenti, Paula Mascarell, Ángela Botella, Félix Gutiérrez   +9 more
doaj   +1 more source

Editorial: choosing new targets for rheumatoid arthritis therapeutics: too interesting to fail? [PDF]

, 2017
No abstract ...
McInnes, Iain B., Porter, Duncan, Siebert, Stefan   +2 more
core   +1 more source

Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE

Rheumatology and Therapy, 2020
Introduction Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK 2, which has demonstrated significant efficacy in patients with moderately to severely active rheumatoid arthritis (RA).
Yue Yang, Xing-Fu Li, Xiao Zhang, Chun-De Bao, Jian-Kang Hu, Jian-Hua Xu, Xiang-Pei Li, Jian Xu, Dong-Yi He, Zhi-Jun Li, Guo-Chun Wang, Han-Jun Wu, Fei Ji, Lu-Jing Zhan, Cristiano A. F. Zerbini, Zhan-Guo Li   +15 more
doaj   +1 more source

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: Results from the RA-BUILD study [PDF]

, 2017
Background Baricitinib is an oral, reversible, selective Janus kinase 1 and 2 inhibitor. Methods In this phase III, double-blind 24-week study, 684 biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with rheumatoid arthritis and ...
Aletaha, Aletaha, Carol Gaich, Douglas Schlichting, Désirée van der Heijde, Edit Drescher, Eli Lilly and Company, Eli Lilly and Company, Eli Lilly and Company, Eli Lilly and Company, Eli Lilly and Company, Felson, Felson, Fries, Fries, Genovese, Genovese, Huizinga, Inmaculada de la Torre, Jiajun Liu, Keystone, Kremer, Maria Greenwald, Maxime Dougados, O'Shea, Papp, Paul Emery, Prevoo, Sarah Witt, Scott Beattie, Skoda, Smolen, Smolen, Smolen, Stephanie de Bono, Takeuchi, Tanaka, Terence Rooney, van der Heijde, van der Heijde, Westhovens, Yamane, Ying-Chou Chen, Zhang   +43 more
core   +2 more sources

Baricitinib is Effective in Treating Progressing Vitiligo in vivo and in vitro

Dose-Response, 2022
Objective To evaluate the clinical efficacy and safety of baricitinib, a Janus kinase (JAK) inhibitor, in treating patient with progressing vitiligo, and to further explore the regulation of baricitinib on melanocytes (MCs) in vitro.
Jie Dong, Xuan Huang, Li-Ping Ma, Fei Qi, Si-Nian Wang, Zi-Qin Zhang, Shi-Nan Wei, Ling Gao, Fang Liu   +8 more
doaj   +1 more source

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis [PDF]

, 2017
Objectives: To evaluate the effect of baricitinib on patient-reported outcomes (PROs) in patients with active rheumatoid arthritis (RA) and an inadequate response or intolerance to conventional synthetic disease-modifying antirheumatic drugs. Methods: In
Brazier, Brooks, Bruce, Carr, Cella, Dougados, Emery, EuroQol Group, Fries, Gossec, Herdman, Keystone, Keystone, Keystone, Klarenbeek, Kosinski, Kosinski, Kremer, O'Shea, Orbai, Pollard, Ramey, Reilly, Sanderson, Schiff, Scott, Sherrer, Singh, Smolen, Smolen, Sokka, Strand, Strand, Strand, Strand, Taylor, Ware, Wells   +37 more
core   +2 more sources

Immunopathogenesis of rheumatoid arthritis [PDF]

, 2017
Rheumatoid arthritis (RA) is the most common inflammatory arthropathy. The majority of evidence, derived from genetics, tissue analyses, models, and clinical studies, points to an immune-mediated etiology associated with stromal tissue dysregulation that
Ahmed, Ai, Ai, Anzilotti, Arend, Astorri, Benham, Bombardieri, Bottini, Bottini, Byng-Maddick, Catrina, Catrina, Charles-Schoeman, Christophorou, Corsiero, Croft, de Aquino, de Hair, Deane, Dennis, Diarra, Ekwall, El-Gabalawy, Ferreira, Filer, Firestein, Firestein, Firestein, Firestein, Firestein, Fonseca, Franz, Gary S. Firestein, Genovese, Hammaker, Harre, Hill, Horiuchi, Huber, Iain B. McInnes, Joosten, Juarez, Kaminsky, Karouzakis, Kelly, Kiener, Kim, Kinslow, Kirschmann, Klarenbeek, Konig, Konig, Krishnadas, Krishnamurthy, Källberg, Langley, Law, Lee, Lefèvre, Linn-Rasker, Liu, Lubberts, Lundström, Makrygiannakis, Matsumoto, McInnes, McInnes, McInnes, McInnes, McKellar, Miossec, Mydel, Müller-Ladner, Nakamachi, Nakano, Nakano, Nam, Okada, Pap, Perlman, Pitzalis, Randen, Rawlings, Raychaudhuri, Raza, Reynisdottir, Reynisdottir, Robertson, Rodríguez-Carrio, Rombouts, Rossetti, Scally, Scher, Schiff, Shi, Shi, Smolen, Smolen, Snir, Sokolove, Stanczyk, Suzuki, Tan, Tran, Tsaprouni, van Beers, van der Helm-van Mil, Vassallo, Wang, Wegner, Weyand, Yamamoto, Yang, Zhang, Zvaifler   +115 more
core   +1 more source

Crosstalk between the JAK2 and TGF-β1 signaling pathways in scleroderma-related interstitial lung disease targeted by baricitinib

Advances in Rheumatology, 2023
Background and objective Systemic sclerosis (SSc) is an immune-mediated rheumatic disease characterized by fibrosis and vascular lesions. Interstitial lung disease is an early complication of SSc and the main cause of death from SSc. Although baricitinib
Dandan Wang, Yimei Wei, Lulu Xu, Jie Zhang   +3 more
doaj   +1 more source